Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00418249

Enrollment

Registered

2007-01-04

Start date

Unknown

Completion date

Unknown

Last updated

2007-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia

Keywords

Androgenetic Alopecia, Telogen effluvium, Chronic telogen effluvium, Menopause, Female Androgenetic Alopecia (FAGA)

Brief summary

The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.

Interventions

DRUGAS101

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women in menopause, over 50 years of age. * Clinically diagnosed for AGA, according to Ludwig scale I-II.

Exclusion criteria

* Women treated with chronic medications. * Use of Minoxidil within 3 months prior to entering study. * Women who have underwent hair transplantation. * Use of drugs with androgenic or anti-androgenic effects. * Any other type of hair loss.

Design outcomes

Primary

Measure	Time frame
hair density	—

Secondary

Measure	Time frame
Hair diameter, anagen/telogen ratio and hair growth rate,Global photographic assessment according to Female-Ludwig scale,	—
Self-administered satisfaction questionnaire	—

Countries

Israel

Contacts

Primary ContactDanny Ben Amitai, MD

972-3-9253770

Backup ContactRaziel Lurie, MD

rlurie@bezeqint.net

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026